Search results :

FK463

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: J02AX05

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5
Gastrointestinal disorder 32.1% - 100% x x x x x
Mediastinal disorder 16.1% - 69.8% x x x x x
Malnutrition 37.8% - 41.1% x x x x x
Infection 30.6% - 40.1% x
Infestation NOS 30.6% - 40.1% x x x
Unspecified disorder of skin and subcutaneous tissue postmarketing, 14.3% - 79.2% x x x x x
Cardiac disorder 5.36% - 35.4% x x x x x
Nervous system disorder 10.5% - 20.8% x x x x x
Mental disorder 1.79% - 46.5% x x x x x
Hypokalaemia 14% - 16.8% x x x x
Vomiting 2.5% - 66.7% x x x x x
Body temperature increased 7% - 64.6% x x x x x
Neutropenia 5.36% - 76.7% x
Anaemia 2.5% - 51.2% x x x x x
Blood and lymphatic system disorders postmarketing, 23.2% - 93% x x x x x
Rash 1.79% - 30.2% x x x x x
Pruritus 0% - 32.6% x x x x x
Diarrhoea 7.14% - 64.6% x x x x x
Nausea 2.8% - 69.8% x x x x x
Epistaxis 0% - 16.7% x x x
Hypotension 5.94% - 10% x x x x
Thrombocytopenia 3.96% - 77.1% x x x x x
Anxiety 0% - 23.3% x x x x
Abdominal distension 1.79% - 18.6% x
Hypoglycaemia 4.66% - 6.93% x x x
Oedema peripheral 5.5% - 7.25% x x x
Bacteraemia 5% - 8.91% x x
Sepsis 4.95% - 5.7% x x x
Insomnia 3.96% - 8.29% x x x x
Alanine aminotransferase increased 0% - 16.3% x x x x x
Infusion related reaction 0% - 16.3% x
Tachycardia 1.79% - 25% x x x x x
Urticaria 0% - 18.6% x x x x x
Headache 2% - 5.7% x x x x x
Hypertension 3% - 6.22% x x x x
Blood alkaline phosphatase increased 2.7% - 7.92% x x x x x
Febrile neutropenia 0% - 16.3% x x x x
Decubitus ulcer 4.5% - 5.94% x x
Septic shock 4.46% - 7.5% x x
Abdominal pain 1.98% - 34.9% x x x x x
Hypernatraemia 4% - 6.44% x x x
Bradycardia 2.5% - 4.95% x x x
Hyperkalaemia 2.59% - 5% x x x x
Haematuria 0% - 23.3% x
Oliguria 0% - 23.3% x x x x
Urinary tract disorder postmarketing, 7.14% - 37.2% x x x x x
Hypomagnesaemia 0% - 8.42% x x x x
Anaemia NOS aggravated 2% - 4.95% x x
Aspartate aminotransferase increased 2.3% x x x x x
Pneumonia 1.5% - 5.45% x x x
Liver function test abnormal 1.5% x x x x x
Atrial fibrillation 0% - 4.95% x x x
Haemolytic anaemia postmarketing x x x x
Disseminated intravascular coagulation postmarketing x x
Toxic epidermal necrolysis postmarketing x x
Hyperbilirubinaemia postmarketing x x x x x
Renal failure acute postmarketing x x x x
Liver disorder postmarketing x x x x
Shock postmarketing x x x x x
Stevens-Johnson syndrome postmarketing x x
Angiopathy postmarketing, 18.7% - 23.3% x x x x x
Hepatic function abnormal postmarketing x x x x
Hepatocellular injury postmarketing x x x x x
Hepatobiliary disease postmarketing x x x x x
White blood cell count decreased postmarketing x x x
Renal impairment postmarketing x x x x x
Acidosis x x x
Acquired immunodeficiency syndrome x
Anaphylactic shock x x
Anorexia x x x x
Anuria x x x
Apnoea x x x
Arrhythmia x x x
Arthralgia x x x
Aspergillosis x
Back pain x x
Coagulopathy x x x x
Bone disorder x x x
Neoplasm malignant x
Cholestasis x
Confusional state x
Connective tissue disorder x x
Constipation x x x x
Cough x x
Cyanosis x x x
Delirium x x x x
Dizziness 0% x x x x
Dysgeusia x x
Dyspepsia x x x x
Dyspnoea x x x x
Endocrine disorder x
Eosinophilia 0% x x
Erythema multiforme x x x x
Fatigue 0% x x x
Flushing x x x x
Cardiac arrest x x x x
Haemoglobinuria x x x
Haemolysis x
Hepatitis x
Hepatomegaly x x x x x
Hiccups x
Hyperglycaemia x x
Hyperhidrosis x
Hypersensitivity x x x
Hypocalcaemia x x x x
Hyponatraemia x x x x
Immune system disorder x x
Inflammation x
Jaundice x x x x x
Nephropathy x
Leukopenia x x
Lymphopenia x
Fungal infection x
Myocardial infarction x x x x
Palpitations x
Pancytopenia x x x x x
Pericardial effusion x
Phlebitis x x x x x
Pulmonary embolism x x x
Thrombotic thrombocytopenic purpura x x x x
Renal failure x
Convulsion x x x x
Thrombophlebitis x x x x
Tremor x
Erythema x x x
Encephalopathy x x x x
Hepatic failure x x x x x
Hypophosphataemia x x
Deep vein thrombosis x x x
Blood urea increased x x
Drug level increased x
Swelling face x x x x
Gamma-glutamyltransferase increased x
Haemorrhage intracranial x x x x
Injection site reaction x x x x x
Skin necrosis x x x
Injection site pain x x
Decreased appetite 0% x x x
Abdominal pain upper 0% x x x
Blood creatinine increased x x
Renal failure aggravated x
Hypoalbuminaemia x
Fluid retention x x
Blood bilirubin increased x
Mucosal inflammation x x
Anaphylactoid reaction x
Haematological malignancy x
Rigors 0% x x x x
Transaminases increased x
Toxic skin eruption x
Injection site thrombosis x x x x x
Fluid overload x x
Blood lactate dehydrogenase increased x x
Infusion site inflammation x x
Renal tubular necrosis x x x
Somnolence x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

micafungin / micafungin

Side effects:95
Source:EMA

MICAFUNGIN

Side effects:71
Source:FDA Structured Product Label

MICAFUNGIN SODIUM / MYCAMINE

Side effects:102
Source:FDA

MICAFUNGIN SODIUM / MYCAMINE

Side effects:109
Source:FDA

MICAFUNGIN SODIUM / MYCAMINE

Side effects:110
Source:Health Canada

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label